Compare Merck & Co., Inc. (MRK) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs United States Oil ETF — how do they compare? Merck & Co., Inc. trades at $146.63 (market cap $351.28B), while United States Oil ETF trades at $148.15 (market cap $1.90B). The key difference: Merck & Co., Inc. is far larger — about 184.9× United States Oil ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and United States Oil ETF for 21 Days on average.
| MRK | USO | |
|---|---|---|
Market Cap | $351.28B | $1.90B |
Volume | 7,969,665 | 5,932,922 |
Sector | Health | — |
52-Week High | $156.43 | $161.86 |
52-Week Low | $82.49 | $66.17 |
Typical Hold Time | 98 Days | 21 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
USO is trading at $147.835, up 2.73% with a bullish technical signal from moving averages. The stock shows neutral oscillators but faces mixed oil market conditions with Middle East tensions and G-7 reserve releases creating volatility. Recent news highlights supply disruptions and geopolitical risks affecting crude prices.
The outlook remains cautious with geopolitical risks and supply uncertainties balancing against potential price support from production constraints. Investment opportunities exist if supply disruptions persist, but risks include regulatory pressures and volatile oil markets that could impact shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
